Cargando…

Analysis of High-Risk Extramedullary Relapse Factors in Newly Diagnosed MM Patients

SIMPLE SUMMARY: Extramedullary relapse of multiple myeloma (MM) is often resistant to existing treatments, and has an extremely poor prognosis. Therefore, early identification of high-risk extramedullary relapse patients has important clinical significance. However, due to the lack of a large prospe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yue, Xiaoyan, He, Donghua, Zheng, Gaofeng, Yang, Yang, Han, Xiaoyan, Li, Yi, Zhao, Yi, Wu, Wenjun, Chen, Qingxiao, Zhang, Enfang, Cai, Zhen, He, Jingsong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776506/ https://www.ncbi.nlm.nih.gov/pubmed/36551591 http://dx.doi.org/10.3390/cancers14246106

Ejemplares similares

Multiple Extramedullary-Bone Related and/or Extramedullary Extraosseous Are Independent Poor Prognostic Factors in Patients With Newly Diagnosed Multiple Myeloma
por: He, JingSong, et al.
Publicado: (2021)

High serum IL-17A is associated with bone destruction in newly diagnosed multiple myeloma patients
por: Dong, Mengmeng, et al.
Publicado: (2022)

Bortezomib-Based Regimens for Newly Diagnosed Multiple Myeloma in China: A Report of 12-Year Real-World Data
por: He, Jingsong, et al.
Publicado: (2020)

Efficacy of Intermittent, Oral Famciclovir Prophylaxis for Bortezomib-Induced Herpes Zoster in Multiple Myeloma Patients
por: Zheng, Gaofeng, et al.
Publicado: (2022)

Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Data in China
por: Han, Xiaoyan, et al.
Publicado: (2021)

Corrigendum: Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Data in China
por: Han, Xiaoyan, et al.
Publicado: (2021)

Baseline peripheral neuropathy was associated with age and a prognostic factor in newly diagnosed multiple myeloma patients
por: Dong, Mengmeng, et al.
Publicado: (2022)

The adverse impact of a gain in chromosome 1q on the prognosis of multiple myeloma treated with bortezomib-based regimens: A retrospective single-center study in China
por: Chen, Qingxiao, et al.
Publicado: (2022)

Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway
por: Yang, Li, et al.
Publicado: (2018)

The Choice of Regimens Based on Bortezomib for Patients with Newly Diagnosed Multiple Myeloma
por: He, Jingsong, et al.
Publicado: (2014)

HMGB1 knockdown increases MM cell vulnerability by regulating autophagy and DNA damage repair
por: Guo, Xing, et al.
Publicado: (2018)

Camalexin Induces Apoptosis via the ROS-ER Stress-Mitochondrial Apoptosis Pathway in AML Cells
por: Yang, Yang, et al.
Publicado: (2018)

The Clinical Characteristics and Prognosis of Chinese Patients with Light-Chain Amyloidosis: A Retrospective Multicenter Analysis
por: He, Donghua, et al.
Publicado: (2021)

Vernodalol mediates antitumor effects in acute promyelocytic leukemia cells
por: Wu, Wenjun, et al.
Publicado: (2018)

Acute myeloid leukemia with CPSF6–RARG fusion resembling acute promyelocytic leukemia with extramedullary infiltration
por: Han, Xiaoyan, et al.
Publicado: (2021)

Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies
por: Yue, XiaoYan, et al.
Publicado: (2020)

BAFF is involved in macrophage-induced bortezomib resistance in myeloma
por: Chen, Jing, et al.
Publicado: (2017)

Quercetin induces cell apoptosis of myeloma and displays a synergistic effect with dexamethasone in vitro and in vivo xenograft models
por: He, Donghua, et al.
Publicado: (2016)

Clinical implications of c-maf expression in plasma cells from patients with multiple myeloma
por: Wei, GuoQing, et al.
Publicado: (2017)

Clinical features of multiple myeloma patients with isolated extramedullary relapse
por: Qu, Xiaoyan, et al.
Publicado: (2018)

P934: THE EFFECTS OF EXTRAMEDULLARY DISEASE ON OUTCOMES OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
por: Tao, Yi, et al.
Publicado: (2023)

Acupuncture combined with methylcobalamin for the treatment of chemotherapy-induced peripheral neuropathy in patients with multiple myeloma
por: Han, Xiaoyan, et al.
Publicado: (2017)

PB2496: CAR-T CELLS THERAPY COMBINED WITH POMALIDOMIDE AGAINST RELAPSE AND REFRACTORY MM OR ALL WITH EXTRAMEDULLARY INVOLVEMENT
por: Zhao, Jie, et al.
Publicado: (2023)

Interleukin-32α promotes the proliferation of multiple myeloma cells by inducing production of IL-6 in bone marrow stromal cells
por: Lin, Xuanru, et al.
Publicado: (2017)

Genotyping on ctDNA Identifies Shifts in Mutation Spectrum Between Newly Diagnosed and Relapse/Refractory DLBCL
por: Liu, Hui, et al.
Publicado: (2020)

Fibroblast activation protein α in tumor microenvironment: Recent progression and implications (Review)
por: ZI, FUMING, et al.
Publicado: (2015)

Distinct Clinical Outcomes between Paramedullary and Extramedullary Lesions in Newly Diagnosed Multiple Myeloma
por: Batsukh, Khishigjargal, et al.
Publicado: (2017)

Tumor Flare Reaction in a Classic Hodgkin Lymphoma Patient Treated With Brentuximab Vedotin and Tislelizumab: A Case Report
por: Zhu, Chunting, et al.
Publicado: (2022)

Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease
por: He, Jingsong, et al.
Publicado: (2018)

Clinical Efficacy of Bendamustine Plus Rituximab (BR) for B-cell Relevant Indolent Non-Hodgkin's Lymphoma and Role of β2-MG in Predicting the Efficacy of BR Regimen: A Real-World Retrospective Study in China
por: Zhang, Yujie, et al.
Publicado: (2022)

Comparison of two serum free light chain assays for the diagnosis of primary plasma cell malignant proliferative disease
por: Yang, Yang, et al.
Publicado: (2019)

Bone-Related Extramedullary Disease in Newly Diagnosed Myeloma Patients is an Independent Poor Prognostic Predictor
por: Wang, Ying, et al.
Publicado: (2022)

Astrocytoma development following complete multiple myeloma remission in a 49-year-old patient: A case report
por: HAN, XIAOYAN, et al.
Publicado: (2013)

Bilateral Conjunctival Infiltration as an Extramedullary Relapse of AML
por: Mozaheb, Zahra, et al.
Publicado: (2018)

Newly diagnosed isolated myeloid sarcoma–paired NGS panel analysis of extramedullary tumor and bone marrow
por: Engel, Nils W., et al.
Publicado: (2020)

The many substrates and functions of NEDD4-1
por: Huang, Xi, et al.
Publicado: (2019)

The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents
por: Romano, Alessandra, et al.
Publicado: (2017)

Advances in the treatment of extramedullary disease in multiple myeloma
por: Li, Yating, et al.
Publicado: (2022)

Acute myeloid leukemia patient with FLT3-ITD and NPM1 double mutation should undergo allogeneic hematopoietic stem cell transplantation in CR1 for better prognosis
por: Huang, Yan, et al.
Publicado: (2019)

Incidental Discovery of Multiorgan Extramedullary Plasmacytomas in the Setting of Newly Diagnosed Multiple Myeloma and Delayed Hemolytic Transfusion Reaction
por: Cook, Joselle, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_nhfmpebqrabqlalu8ctt0jh986